Tepotinib-Induced Cholangitis in a Patient With Non-Small Cell Lung Cancer: A Case Report

Tepotinib, a mesenchymal epithelial transition factor (MET) tyrosine kinase inhibitor, is used to treat non-small cell lung cancer with MET exon 14 skipping mutations. Although hepatotoxicity has been reported, drug-induced cholangitis has not been reported before. Here, we report a case of tepotinib-induced cholangitis in a 77-year-old woman with preexisting primary biliary cholangitis. During tepotinib treatment, the patient experienced abdominal pain along with elevated hepatobiliary enzyme levels. Imaging and histological examinations revealed findings similar to sclerosing cholangitis. The liver enzyme levels decreased after drug discontinuation. This case highlights the need for careful monitoring of hepatobiliary function when prescribing MET inhibitors, particularly in patients with underlying liver disease.